List of Papers Browse by Subject Areas Author List
Abstract
We propose a novel approach to bridge the resolution and dimensionality gap between CTA, which provides 3D vascular geometry but often misses small vessels, and biplanar 2D DSA, which offers higher spatial resolution but lacks 3D structural information, by formulating the problem as a 3D shape completion task.
Our method represents vasculature using a set of 3D Gaussians initialized from CTA-derived vessel geometry and augmented with additional spatial and opacity primitives seeded from two DSA projections. These Gaussians jointly encode geometry and attenuation and are optimized to fit the observed DSA images while remaining consistent with the original CTA anatomy.
Experiments on synthetic and clinical cerebrovascular data demonstrate improved 3D reconstruction of small vessel branches at submillimetric resolution, validating the use of DSA to complement missing CTA vessel anatomy.
Links to Paper and Supplementary Materials
Main Paper (Open Access Version): https://papers.miccai.org/miccai-2026/paper/2705_paper.pdf
SharedIt Link: Not yet available
SpringerLink (DOI): Not yet available
Supplementary Material: https://papers.miccai.org/miccai-2026/supp/2705_supp.zip
Link to the Code Repository
https://github.com/janik-j/cta-dsa-fusion
Link to the Dataset(s)
TopBrain CTA Dataset: https://topbrain2025.grand-challenge.org/data/
Clinical CTA/DSA dataset (Brigham and Women’s Hospital): Not publicly available due to PHI constraints
BibTex
@InProceedings{JehJan_3D_MICCAI2026,
author = { Jehkul, Janik AND Frisken, Sarah AND Gopalakrishnan, Vivek AND Rueckert, Daniel AND Haouchine, Nazim},
title = { { 3D Cerebrovascular Shape Completion from Biplane Angiography and CTA Prior } },
booktitle = {Medical Image Computing and Computer Assisted Intervention -- MICCAI 2026},
year = {2026},
publisher = {Springer Nature Switzerland},
volume = {LNCS 16889},
month = {September},
page = {pending}
}
Reviews
Review #1
- Please describe the contribution of the paper
This work presents a Gaussian splatting-based method to reconstruct 3D mesh from bi-plane DSA, using the pre-operative CTA as the prior.
- Please list the major strengths of the paper: you should highlight a novel formulation, an original way to use data, demonstration of clinical feasibility, a novel application, a particularly strong evaluation, or anything else that is a strong aspect of this work. Please provide details, for instance, if a method is novel, explain what aspect is novel and why this is interesting.
1.The proposed method seems to outperform the SOTA methods based on qualitative and quantitative assessments. 2.Loss functions are tailored to the task. 3.The ablation studies are comprehensive and clearly demonstrate the contribution of each component.
- Please list the major weaknesses of the paper. Please provide details: for instance, if you state that a formulation, way of using data, demonstration of clinical feasibility, or application is not novel, then you must provide specific references to prior work.
1.Only a subset of TopBrain CTA data was used, but the authors didn’t provide the reason why they exclude the rest. 2.The DSA data were synthesised from CTA, which could be unreliable. In reality, CTA can visualise full cerebral vasculature whereas DSA only visualise part of it, because of the difference in the contrast injection methods (intravenous vs intra-arterial). In addition, there might be variation due to contrast agent dispersion. The authors should provide further information on how the DSA data synthesis was performed. 3.The method was tested on only three patients with acquired DSA and CTA. The projection of the reconstructed mesh seemingly agrees well with the original DSA in Patient 1.However, visual assessment based on the provided 3D meshes is very difficult for Patient 2 & 3 and unable to confirm successful reconstruction.
- Please rate the clarity and organization of this paper
Satisfactory
- Please comment on the reproducibility of the paper. Please be aware that providing code and data is a plus, but not a requirement for acceptance.
The authors claimed to release the source code and/or dataset upon acceptance of the submission.
- Based on your review and your understanding of the MICCAI Scientific Code of Ethics, do you believe this submission may involve a potential ethics concern or violation?
N/A
- Optional: If you have any additional comments to share with the authors, please provide them here. Please also refer to our Reviewer’s guide on what makes a good review and pay specific attention to the different assessment criteria for the different paper categories: https://conferences.miccai.org/2026/en/REVIEWER-GUIDELINES.html
1.The proposed method relies on CTA/DSA registration for real world application. How reliable is the registration used in this work and how significant would registration errors affect the final result? 2.The method employs multiple loss terms—could the authors elaborate on how their weights were balanced? Table 2 shows that combining all the designated losses does not achieve the best performance. Please provide further discussion. 3.(Figure 4) Why is the internal carotid artery missing in the incomplete mesh in every patient? As the main artery, it should be easily identified at initialisation.
- Rate the paper on a scale of 1-6, 6 being the strongest (6-4: accept; 3-1: reject). Please use the entire range of the distribution. Spreading the score helps create a distribution for decision-making.
(3) Weak Reject — marginally below the acceptance threshold, but would not mind if accepted, dependent on rebuttal
- Please justify your recommendation. What were the major factors that led you to your overall score for this paper?
I am not convinced that the proposed method has achieved the claimed sucess.
- Reviewer confidence
Confident but not absolutely certain (3)
- [Post rebuttal] After reading the authors’ rebuttal, please state your final opinion of the paper.
Accept
- [Post rebuttal] Please justify your final decision from above.
The authors have addressed most of the previous concerns. Importantly, they have agreed to update Fig 4 to improve visualisation and to support the claims. While the small in vivo dataset of three patients makes the validation qualitative and speculative, it might be sufficient for proof of concept. Overall, the recommendation is acceptance.
Review #2
- Please describe the contribution of the paper
The paper proposes a 3D cerebrovascular shape-completion method that combines an incomplete CTA-derived vessel prior with two biplane DSA projections. The core idea is to represent the vasculature using 3D Gaussians initialized from both the CTA mesh and DSA-derived residual context points, and then optimize them with a rendering loss, a false-negative vessel loss, and a prior-anchoring regularizer.
- Please list the major strengths of the paper: you should highlight a novel formulation, an original way to use data, demonstration of clinical feasibility, a novel application, a particularly strong evaluation, or anything else that is a strong aspect of this work. Please provide details, for instance, if a method is novel, explain what aspect is novel and why this is interesting.
- The paper addresses a clinically meaningful problem. CTA provides 3D structure but, as the authors stress, often misses small distal vessels, while biplane DSA has higher spatial resolution but only 2D information. Thus, framing this as shape completion from a patient-specific CTA prior plus biplane DSA is a strong and well-motivated formulation
- The method itself is technically interesting. The combination of dual-source Gaussian initialization, differentiable X-ray rasterization, a false-negative loss targeted at weakly supervised thin branches, and a prior-anchoring term is coherent and well aligned with the imaging physics and the stated goal of vessel completion rather than generic reconstruction. Overall, it feels like a quite interesting and novel approach
- Quantitative results are strong on the synthetic benchmark. The method clearly outperforms the reported baselines in both 2-view and 3-view settings
- The paper also includes meaningful ablation studies on losses, initialization strategy, and prior completeness
- The paper includes an initial clinical demonstration. Although a bit limited, the three-patient qualitative study supports the claim that the method can recover distal branches visible in DSA but absent from CTA
- Please list the major weaknesses of the paper. Please provide details: for instance, if you state that a formulation, way of using data, demonstration of clinical feasibility, or application is not novel, then you must provide specific references to prior work.
- The main weakness is the limited real-world validation. Quantitative experiments are performed on only 10 synthetic CTA scans with simulated incomplete priors, while the clinical study covers only 3 patients and is qualitative only. There is no paired clinical ground truth or quantitative evaluation on real patient data, so it is still unclear how robust the method is under realistic acquisition artifacts, contrast inhomogeneity, and registration error
- A second weakness is that the novelty is somewhat incremental at the problem level, even if the specific combination is novel. Prior work has already studied two-view cerebral vascular reconstruction and learned priors for this setting (e.g., “Two Projections Suffice for Cerebral Vascular Reconstruction” by Frisken et al.). The novelty of the present paper lies more in the CTA-guided Gaussian splatting completion formulation than in introducing the two-view reconstruction problem itself
- A more minor weakness is that reproducibility is only partial in the current version. The paper gives the overall formulation and some hyperparameters, but several implementation details appear under-specified in the main text, such as some initialization and threshold choices for the auxiliary terms and prior neighborhood construction
- Please rate the clarity and organization of this paper
Good
- Please comment on the reproducibility of the paper. Please be aware that providing code and data is a plus, but not a requirement for acceptance.
The authors claimed to release the source code and/or dataset upon acceptance of the submission.
- Based on your review and your understanding of the MICCAI Scientific Code of Ethics, do you believe this submission may involve a potential ethics concern or violation?
N/A
- Optional: If you have any additional comments to share with the authors, please provide them here. Please also refer to our Reviewer’s guide on what makes a good review and pay specific attention to the different assessment criteria for the different paper categories: https://conferences.miccai.org/2026/en/REVIEWER-GUIDELINES.html
I think it’s an interesting paper overall and well-written. I liked the idea of using a CTA prior to somewhat turn biplane DSA reconstruction into a completion problem rather than a purely unconstrained inverse problem. The ablations are helpful and the improvements on the synthetic benchmark are convincing.
The main issue for me is validation. The paper would be significantly stronger with either quantitative evaluation on clinical data or a more realistic simulation study that better captures registration error, residual subtraction artifacts, and contrast inhomogeneity.
- Rate the paper on a scale of 1-6, 6 being the strongest (6-4: accept; 3-1: reject). Please use the entire range of the distribution. Spreading the score helps create a distribution for decision-making.
(4) Weak Accept — marginally above the acceptance threshold, but would not mind if rejected, dependent on rebuttal
- Please justify your recommendation. What were the major factors that led you to your overall score for this paper?
I am leaning weak accept because the paper presents a solid and clinically relevant methodological contribution: a well-motivated CTA-guided Gaussian-splatting formulation for completing cerebrovascular anatomy from only two DSA views. The quantitative gains over the reported baselines are substantial, and the ablations help support the design choices.
At the same time, the evidence for real-world clinical utility is still limited. The quantitative study is small and synthetic, and the clinical evaluation is qualitative on only three patients.
So to summarize, I find the idea strong and potentially impactful but I think the paper still sits near the threshold because the empirical validation does not yet fully match the ambition of the claims.
- Reviewer confidence
Very confident (4)
- [Post rebuttal] After reading the authors’ rebuttal, please state your final opinion of the paper.
Accept
- [Post rebuttal] Please justify your final decision from above.
I believe the authors have adequately addressed the concerns raised in my review. I am satisfied with the authors’ response.
Review #3
- Please describe the contribution of the paper
Authors are proposing taking advantage of imaging methods with higher resolution to complement imaging methods with a lower resolution. In this case, completing the vasculature observed in CTA which in most hospital setups can go up to 0.5mm (or 0.83mm in the particular clinical evaluation of this paper), with the one observed in DSA acquisitions, the gold standard in many neurovascular diseases like stroke, which tend to go up to 0.2mm. Particularly helpful in treatment of small aneurysms, stroke and potentially calcification in distal vessels. Authors method to complete the vasculature uses dual initialization, one using a prior mesh from the CTA and DSA biplanar projections (improved with a third oblique view). Loss function includes a rendering component, a false negative vessel loss and a prior anchoring regularizer, to cover all the aspects of the method. Method is evaluated on both synthetic and clinical datasets (n=10 and n=3 respectively).
- Please list the major strengths of the paper: you should highlight a novel formulation, an original way to use data, demonstration of clinical feasibility, a novel application, a particularly strong evaluation, or anything else that is a strong aspect of this work. Please provide details, for instance, if a method is novel, explain what aspect is novel and why this is interesting.
Complete reconstruction of distal vessels having just 3 or even two additional DSA planes and extend the baseline CTA is a great piece of work. Not only because of the extension of diagnostic tools, but also because particular neurovascular diseases whose gold standard diagnostic image is DSA will benefit from having complete distal information for treatment planning.
The loss function covers important aspects of the proposed method: how good is the render, regularize on the priors and check false negative on distal branches. The term is well thought and parameters of the training objective are well defined (potentially tuned). False loss term makes sense since the original name and main method is the study on the contribution of sparse (biplanar) DSA, however is worth asking on the review side, is it the same parameter value when using the oblique view? Given the fact of how much it improves the results. Are the terms performing the same on the both biplanar and triplanar setups?
- Please list the major weaknesses of the paper. Please provide details: for instance, if you state that a formulation, way of using data, demonstration of clinical feasibility, or application is not novel, then you must provide specific references to prior work.
While the community broadly accepts demonstrations of clinical feasibility on small cohorts, the clinical evaluation (n=3) remains exclusively qualitative. Given that the paper explicitly claims clinical applicability and demonstrates recovery of 0.216mm vessels within 0.833mm CTA resolution, it would be interesting to disclose quantitative metrics for the clinical cases. Was the decision to keep this qualitative a consequence of annotation difficulty, or was there a deliberate methodological reason? Clarifying this would help readers assess the generalizability of the results. The method’s performance somehow relies on accurate 2D-3D registration between DSA planes and the CTA-derived mesh. However, no registration error analysis or sensitivity study is provided. Understanding there are space limitations and authors covered quite well the complete explanation, a small discussion on how robust the pipeline is to misalignment would be good. A small extension of the previous point is that you had space enough to cover a context point initialization ablation, however information of this table is limited. It is interesting why having less context points (only M1) perform better than uniform initialization.
- Please rate the clarity and organization of this paper
Good
- Please comment on the reproducibility of the paper. Please be aware that providing code and data is a plus, but not a requirement for acceptance.
The authors claimed to release the source code and/or dataset upon acceptance of the submission.
- Based on your review and your understanding of the MICCAI Scientific Code of Ethics, do you believe this submission may involve a potential ethics concern or violation?
N/A
- Optional: If you have any additional comments to share with the authors, please provide them here. Please also refer to our Reviewer’s guide on what makes a good review and pay specific attention to the different assessment criteria for the different paper categories: https://conferences.miccai.org/2026/en/REVIEWER-GUIDELINES.html
N/A
- Rate the paper on a scale of 1-6, 6 being the strongest (6-4: accept; 3-1: reject). Please use the entire range of the distribution. Spreading the score helps create a distribution for decision-making.
(4) Weak Accept — marginally above the acceptance threshold, but would not mind if rejected, dependent on rebuttal
- Please justify your recommendation. What were the major factors that led you to your overall score for this paper?
The paper presents a technically well explained method and a clinically motivated contribution at the using CTA and DSA imaging. The synthetic evaluation is well thought, the loss design is well motivated, and the gains from adding a third oblique plane are really notable. The contribution is novel and the clinical framing is, at least, relevant to diseases like stroke. The score is Weak Accept given the absence of quantitative metrics (CD, HD) in the clinical evaluation needs justification, if it was a deliberate design decision or an annotation constraint should be explicitly stated. Registration quality between DSA can be commented/expanded, as well as how brief was table 3 commented.
- Reviewer confidence
Confident but not absolutely certain (3)
- [Post rebuttal] After reading the authors’ rebuttal, please state your final opinion of the paper.
Accept
- [Post rebuttal] Please justify your final decision from above.
The rebuttal addresses my main concerns directly. The justification for the qualitative-only clinical evaluation, that quantitative ground truth would require CTA acquired at near-DSA resolution, which is not standard in clinical practice, is a methodologically honest answer, and the reframing of the 10 TopBrain cases as the quantitative cohort and the 3 clinical cases as feasibility-under-real-DSA conditions is reasonable, but still quite small, worth noting. The registration response (XVR with sub-mm accuracy, combined with Eq. 5’s KNN-anchored prior absorbing sub-voxel imprecision) explains the design feature that confers robustness, but not explain at all how good does registration need to be, a full sensitivity study would not hurt. The loss-weight clarification at biplane vs triplane answered my question about whether the loss terms perform equivalently across setups The contribution looks good and clinically motivated.
Author Feedback
We are glad reviewers found the problem “clinically meaningful” (R2); our method “novel”, “technically interesting” (R2), and “well explained” (R3) with a “strong and well-motivated” formulation (R2) and losses “tailored to the task” (R1). Reviews also found the results to “outperform[s] the SOTA methods” (R1) and the ablations to be “comprehensive” (R1) and that we overall presented a “great piece of work” (R3). We thank the reviewers for their comments and address the main ones below.
CLINICAL VALIDATION (R1,R2,R3): We presented a quantitative evaluation on 10 TopBrain cases using real CTA and synthetic DSA, including comparisons with SOTA methods, an ablation study, and a sensitivity analysis, along with qualitative results on 3 clinical cases. These additional clinical cases are provided to demonstrate feasibility under real clinical DSA acquisition conditions, not to serve as a statistically powered evaluation cohort. Moreover, quantitative clinical evaluation would require CTA acquisition at a resolution comparable to DSA (to capture tiny vessels), which is not widely acquired in clinical practice. In addition, since our approach is a patient-specific optimization, all 10 cases contribute independently to the results in Tables 1-3, covering different anatomies and vascular variability. Altogether, while we agree that a larger clinical evaluation is beneficial, we believe that our evaluation supports the claims of the paper and is overall on par with related methodological papers in this area.
SYNTHETIC DSA (R1): We agree CTA covers more vasculature than DSA. Our aim is not to match coverage but to use CTA as a prior to reach the sub-mm resolution that only DSA resolves, as stated in the introduction. We forward-project each CTA volume with TIGRE under a simulated cone-beam geometry and subtract mask from fill projections (Sec. 5.1). The clinical input I_v is a temporal MIP (Sec. 2.1), so both inputs reduce to a single static projection per view. R1 rightly notes that real DSA only depicts the injected territory due to IA vs IV contrast administration. The synthesis does not model this, but the clinical pipeline crops M_P to points projecting into DSA vessel masks across all views (Sec. 5.1.2), restricting the prior to the injected territory at input. We will clarify this in the final paper.
TOPBRAIN SUBSET (R1, R2): We had to use a subset of TopBrain to fine-tune DenoiseNet, leaving 10 cases for evaluation. No method sees test data at training time. We will state this split explicitly in the paper.
LOSS WEIGHTS (R1, R3): Each loss targets one error mode by design, so the full configuration is not best on every per-region metric. L_FN improves the missing region HD_ROI by 18%, L_PA the prior region CD_prior by 8%, combined best overall CD. λ_FN and λ_PA are identical at 2 and 3 views with effects more pronounced at 3 views (R3). λ_ssim differs (0 vs 0.07), as we empirically found that pure L1 works better at 2 views.
REGISTRATION (R1, R3): CTA to DSA alignment uses XVR [7] (sub-mm accuracy). The CTA prior is not fixed: Eq. 5 anchors centers to the local mean of their KNN prior points, and the squared norm penalizes large displacements, so sub-voxel imprecision is absorbed without prior drift.
FIGURE 4 AND ICA (R1). We agree that Fig. 4 should be improved to better appreciate p2 and p3 results. We will improve Fig. 4 with larger renderings and zoom-ins in the final version. We provided a supplementary video for 3D inspection. In Fig. 4, the ICA appears reduced in M_P because of a predefined ROI during CTA acquisition. The 3 clinical cases visualize only the LICA territory, since contrast was injected into the left ICA.
DIFFERENCE w.r.t. SOTA (R2): Our method differs from the population models (Cafaro, Zuo/Wu, Frisken) in that we use the patient’s own CTA as a prior, allowing us to reformulate biplane DSA reconstruction as a patient-specific 3D shape completion rather than inverse 3D reconstruction.
Meta-Review
Meta-review #1
- Your recommendation
Invite for Rebuttal
- Please justify your decision. In case you deviate from the reviewers’ recommendations, explain in detail the reasons why. In case of an invitation for rebuttal, clarify which points are important to address in the rebuttal.
This paper proposes a CTA-guided Gaussian splatting framework for 3D cerebrovascular shape completion from biplane DSA.
Reviewers agree the problem could be clinically relevant and the approach is technically interesting, but raise concerns about limited and mostly qualitative clinical validation, reliance on simulated data, and unclear robustness to factors such as DSA synthesis and CTA-DSA registration. I suggest that the authors address these raised concerns in the rebuttal.
- After you have reviewed the rebuttal and updated reviews, please provide your recommendation based on all reviews and the authors’ rebuttal.
Accept
- Please justify your recommendation.
The authors provided a convincing rebuttal, and there is consensus among the reviewers that the paper presents a technically interesting and clinically motivated approach, which could be a valuable feasibility study. Therefore, I recommend acceptance.
Meta-review #2
- After you have reviewed the rebuttal and updated reviews, please provide your recommendation based on all reviews and the authors’ rebuttal.
Accept
- Please justify your recommendation.
The authors have largely clarified the previously unclear points in their rebuttal, and the reviewers appear satisfied with the responses, with all agreeing on acceptance. The AC therefore recommends acceptance.
Meta-review #3
- After you have reviewed the rebuttal and updated reviews, please provide your recommendation based on all reviews and the authors’ rebuttal.
Accept
- Please justify your recommendation.
All reviewers agrees that the authors response were adequate.
